Production (Stage)
Cytek Biosciences, Inc.
CTKB
$2.42
-$0.03-1.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -27.87% | 11.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.87% | 11.60% | |||
| Cost of Revenue | -10.59% | 5.91% | |||
| Gross Profit | -40.10% | 16.02% | |||
| SG&A Expenses | 7.92% | 0.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.15% | 2.41% | |||
| Operating Income | -3,979.53% | 109.09% | |||
| Income Before Tax | -209.13% | 6,475.16% | |||
| Income Tax Expenses | -80.00% | 186.73% | |||
| Earnings from Continuing Operations | -218.24% | 924.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -218.24% | 924.76% | |||
| EBIT | -3,979.53% | 109.09% | |||
| EBITDA | -684.82% | 193.45% | |||
| EPS Basic | -218.88% | 937.50% | |||
| Normalized Basic EPS | -246.79% | 5,242.86% | |||
| EPS Diluted | -226.23% | 890.28% | |||
| Normalized Diluted EPS | -246.79% | 5,242.86% | |||
| Average Basic Shares Outstanding | -0.57% | -1.47% | |||
| Average Diluted Shares Outstanding | -0.57% | -2.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||